Meeting
2020 Genitourinary Cancers Symposium
CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs).
Authors
Laurence Albiges
Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
Laurence Albiges , Manuela Schmidinger , Naila Taguieva Pioger , David Pérol , Viktor Grünwald
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Other
Clinical Trial Registration Number
NCT03945773
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS772)
Abstract #
TPS772
Poster Bd #
L6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
First Author: Laurence Albiges
First Author: Michael Masetti
Poster
2023 ASCO Genitourinary Cancers Symposium
Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021.
First Author: John McGrane
Poster
2021 ASCO Annual Meeting
Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
First Author: Elizabeth R Kessler